Chinese authorities have come up with a study that Favipiravir could be an effective treatment for the symptoms of COVID-19.
COVID-19 is an infectious disease. It is called Coronavirus because its particles exhibit a characteristic corona or crown of spike proteins around its lipid envelope. Symptoms of the disease may be very mild or more serious such as:
⦁ Difficulty breathing
After exposure to the virus, the appearance of the symptoms may take up to 14 days. Some other symptoms may include:
⦁ Aches and pains
COVID-19 can be passed from person to person by droplets from sneezes or coughs. This disease has been detected in people all over the world and is considered a pandemic. The virus can be spread between two people who are in close contact with one another. It may also be through respiratory droplets produced when an infected person sneezes or coughs.
People are thought to be most contagious when they are most symptomatic. Some spread might be possible before people show symptoms.
What is Favipiravir and how it works?
Favipiravir initially was developed by Fujifilm Toyama Chemical as an anti-influenza drug. Japan approved it for clinical use to treat cases of influenza in 2014. Influenza is a viral infection that attacks your respiratory system. For most people, influenza resolves on its own. Sometimes, its complications can be deadly. Initially, the flu may seem like a common cold with a runny nose and sore throat whereas the flu tends to come on suddenly. Although a cold can be a nuisance, you usually feel much worse with the flu. People with the virus are likely contagious from the day or so before symptoms first appear until about 5 days after symptoms begins.
Now, clinical trials in several countires are studying the effectiveness of Favipiravir in combatting COVID-19. It has now good reports. The results were made to let Chinese officials use this medication for study to treat COVID-19. Results showed that patients receiving Favipiravir treatment turned negative for the virus. The researchers also added that, in this open-label non-randomized control study, Favipiravir showed significantly better treatment effects on COVID-19. It may be in terms of disease progression and viral clearance.
The drug is specifically made to treat RNA viruses like SARS-CoV-2. These viruses whose main genetic material is RNA rather than DNA. The drug stops viruses from replicating by crippling the enzyme called RNA polymerase which builds RNA. Without that enzyme intact, the virus can’t duplicate its genetic material efficiently once inside a host cell.
Chinese is also speeding up the process to finalize vaccines to counter COVID-19 amid reports that the reaserch facility in Seattle and Washington starts clinical trial investigational vaccine. Some vaccines for the coronavirus are expected to enter clinical trials as soon as possible. Chinese scientist have been racing to develop COVID-19 vaccines by five apporaches;
- Inactivated Vaccines
- Genetic Engineering Sub-unit Vacciness
- Adenovirus Vector Vaccines
- Nucleic Acid Vaccines
- Vaccines using attenuated influenza virus as Vectors